CareAcross

To hear about similar clinical trials, please enter your email below

I agree to receive (at most) monthly updates on similar research. I retain all GDPR rights. CareAcross will never share my email address.

Trial Title: A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT ID: NCT06392477

Condition: B-cell Non Hodgkin Lymphoma

Conditions: Official terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell

Conditions: Keywords:
B-NHL
Non-Hodgkin Lymphoma
NHL

Study type: Interventional

Study phase: Phase 1

Overall status: Recruiting

Study design:

Allocation: Non-Randomized

Intervention model: Sequential Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: DR-0201
Description: DR-0201 is a bispecific antibody
Arm group label: DL1 of DR-0201
Arm group label: DL2 of DR-0201
Arm group label: DL3 of DR-0201
Arm group label: DL4 of DR-0201
Arm group label: DL5 of DR-0201
Arm group label: DL6 of DR-0201
Arm group label: DL7 of DR-0201
Arm group label: DL8 of DR-0201

Summary: This is a multicenter, multiple expansion cohort, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Criteria for eligibility:
Criteria:
Key Inclusion Criteria: - At least 2 prior lines of therapy and without treatment options that are recognized to offer clinical benefit - Adequate marrow reserve, renal function, and hepatic function - Measurable disease defined as ≥ 1 bi-dimensionally measurable nodal lesion of > 1.5 cm in the longest dimension for subjects with PET avid disease for subtypes with nodular disease or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Life expectancy of ≥ 12 weeks - Use of a highly effective contraceptive measure all males and all females of childbearing potential during study through 180 days post last dose; Females of childbearing potential need to have a negative serum pregnancy test within 7 days prior to first dose. - Tumor tissue block or 3 to 5 unstained slides from lymph node or other relevant biopsy collected in the past 6 months or subject must be willing to provide a baseline biopsy, unless not safely accessible - In subjects with prior CAR-T therapy, >90 days post CAR-T at day of first dosing Key Exclusion Criteria: - Burkitt's or Burkitt's like lymphoma or lymphoplastic lymphoma - Current or past history of central nervous system (CNS) lymphoma - Prior allogeneic stem cell transplantation except for those with FL and MCL, who are excluded if transplant occurred less than 100 days prior to Screening or if they exhibit active signs of or received treatment for graft versus host disease (GvHD) - Prior solid organ transplantation - Autologous stem cell transplantation ≤ 100 days - History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematous, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulamatosis, Sjorgen's syndrome, Guillain-Barre-syndrome, multiple sclerosis vasculitis, or glomerulonephritis (subjects with a remote history of, or well-controlled autoimmune disease, may be eligible) - Major surgery in the last 28 days prior to dosing - Evidence of significant, uncontrolled concomitant disease that could affect compliance with study - Current or past history of CNS disease (Subjects with remote history of non-lymphoma CNS disease and with no residual neurologic deficits may be eligible to enroll) - QT interval corrected by Fridericia's formula (QTcF) > 480 msec - Significant cardiovascular disease - Received systemic therapy with anti-cancer therapies 4 weeks prior to first DR-0201 administration or 5 half-lives of the drug, whatever is shorter. Treatment with corticosteroid ≤ 25mg/day prednisone or equivalent is allowed. Inhaled and topical steroids are allowed. - Prior treatment with systemic immunotherapy agents included, but not limited to radio immunoconjugates, antibody drug conjugates, cytokines, immune checkpoint inhibitors 4 weeks or 5 half-lives of the drug, whatever is shorter - Positive hepatitis B virus (HBV) polymerase chain reaction (PCR) test. Subjects with a positive serologic test for HBV (i.e., positive hepatitis B core antibody [HBcAb] and negative for hepatitis B surface antigen [HBsAg]) must have a negative PCR test - Known infection with HIV, HBV, or hepatitis C virus (HCV). Subjects who are HIV-positive with undetectable HIV RNA and at least 3 months on a highly effective antiviral therapy (HART) and subjects who are HCV-positive who have completed at least 1 month of highly effective antiviral therapy may be eligible. - Acute bacterial, viral, or fungal infection at baseline - Active infection requiring systemic (IV) treatment with antimicrobial, antifungal, or antiviral agents in the 2 weeks prior to dosing. - Administration of a live, attenuated vaccine within 4 weeks prior to first DR-0201 administration or anticipation that such vaccine administration would be necessary during the course of the study - Another invasive malignancy in the last 2 years (except basal cell carcinoma and tumors deemed by the investigator to be of low likelihood for recurrence)

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Dren Investigational Site

Address:
City: Camperdown
Zip: 2050
Country: Australia

Status: Not yet recruiting